Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2014

Open Access 01-12-2014 | Research article

Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer

Authors: Helit Cohen, Rotem Ben-Hamo, Moriah Gidoni, Ilana Yitzhaki, Renana Kozol, Alona Zilberberg, Sol Efroni

Published in: Breast Cancer Research | Issue 6/2014

Login to get access

Abstract

Introduction

GATA binding protein 3 (GATA3) is a regulator of mammary luminal cell differentiation, and an estrogen receptor (ER) associated marker in breast cancer. Tumor suppressor functions of GATA3 have been demonstrated primarily in basal-like breast cancers. Here, we focused on its function in luminal breast cancer, where GATA3 is frequently mutated, and its levels are significantly elevated.

Methods

GATA3 target genes were identified in normal- and luminal cancer- mammary cells by ChIP-seq, followed by examination of the effects of GATA3 expressions and mutations on tumorigenesis-associated genes and processes. Additionally, mutations and expression data of luminal breast cancer patients from The Cancer Genome Atlas were analyzed to characterize genetic signatures associated with GATA3 mutations.

Results

We show that some GATA3 effects shift from tumor suppressing to tumor promoting during tumorigenesis, with deregulation of three genes, BCL2, DACH1, THSD4, representing major GATA3-controlled processes in cancer progression. In addition, we identify an altered activity of mutant GATA3, and distinct associated genetic signatures. These signatures depend on the functional domain mutated; and, for a specific subgroup, are shared with basal-like breast cancer patients, who are a clinical group with regard to considerations of mode of treatment.

Conclusions

The GATA3 dependent mechanisms may call for special considerations for proper prognosis and treatment of patients.
Appendix
Available only for authorised users
Literature
1.
Theodorou V, Stark R, Menon S, Carroll JS: GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2013, 23: 12-22. 10.1101/gr.139469.112.CrossRefPubMedPubMedCentral
2.
Chen Y, Bates DL, Dey R, Chen PH, Machado AC, Laird-Offringa IA, Rohs R, Chen L: DNA binding by GATA transcription factor suggests mechanisms of DNA looping and long-range gene regulation. Cell Rep. 2012, 2: 1197-1206. 10.1016/j.celrep.2012.10.012.CrossRefPubMedPubMedCentral
3.
Oliver CH, Khaled WT, Frend H, Nichols J, Watson CJ: The Stat6-regulated KRAB domain zinc finger protein Zfp157 regulates the balance of lineages in mammary glands and compensates for loss of Gata-3. Genes Dev. 2012, 26: 1086-1097. 10.1101/gad.184051.111.CrossRefPubMedPubMedCentral
4.
Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z: GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006, 127: 1041-1055. 10.1016/j.cell.2006.09.048.CrossRefPubMedPubMedCentral
5.
Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D, Nguyen C: Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet. 2000, 9: 2981-2991. 10.1093/hmg/9.20.2981.CrossRefPubMed
6.
Hoch RV, Thompson DA, Baker RJ, Weigel RJ: GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999, 84: 122-128. 10.1002/(SICI)1097-0215(19990420)84:2<122::AID-IJC5>3.0.CO;2-S.CrossRefPubMed
7.
Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG: Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005, 65: 11259-11264. 10.1158/0008-5472.CAN-05-2495.CrossRefPubMed
8.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
9.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
10.
Parise CA, Bauer KR, Brown MM, Caggiano V: Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009, 15: 593-602. 10.1111/j.1524-4741.2009.00822.x.CrossRefPubMed
11.
Yan W, Cao QJ, Arenas RB, Bentley B, Shao R: GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem. 2010, 285: 14042-14051. 10.1074/jbc.M110.105262.CrossRefPubMedPubMedCentral
12.
Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z: GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 2008, 13: 141-152. 10.1016/j.ccr.2008.01.011.CrossRefPubMedPubMedCentral
13.
Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V, Siegel PM, Bouchard M: GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene. 2009, 28: 2634-2642. 10.1038/onc.2009.126.CrossRefPubMed
14.
Granit RZ, Gabai Y, Hadar T, Karamansha Y, Liberman L, Waldhorn I, Gat-Viks I, Regev A, Maly B, Darash-Yahana M, Peretz T, Ben-Porath I: EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene. 2012, 32: 3886-3895. 10.1038/onc.2012.390.CrossRef
15.
Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, Harkin DP, Mullan PB: BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene. 2012, 31: 3667-3678. 10.1038/onc.2011.531.CrossRefPubMed
16.
Abba MC, Nunez MI, Colussi AG, Croce MV, Segal-Eiras A, Aldaz CM: GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. Breast Cancer Res. 2006, 8: R64-10.1186/bcr1617.CrossRefPubMedPubMedCentral
17.
Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE: GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene. 2012, 31: 2017-2027. 10.1038/onc.2011.382.CrossRefPubMed
18.
Jiang S, Katayama H, Wang J, Li SA, Hong Y, Radvanyi L, Li JJ, Sen S: Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells. Horm Cancer. 2010, 1: 11-20. 10.1007/s12672-010-0006-x.CrossRefPubMedPubMedCentral
19.
Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M: Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res. 2007, 67: 6477-6483. 10.1158/0008-5472.CAN-07-0746.CrossRefPubMed
20.
Kong SL, Li G, Loh SL, Sung WK, Liu ET: Cellular reprogramming by the conjoint action of ERalpha, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol. 2011, 7: 526-10.1038/msb.2011.59.CrossRefPubMedPubMedCentral
21.
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012, 486: 405-409. 10.1038/nature11154.CrossRefPubMedPubMedCentral
22.
Ellis MJ, Ding L: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012, 486: 353-360.PubMedPubMedCentral
23.
Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerod A, Karesen R, Oh DS, Dressler LG, Lonning PE, Strausberg RL, Chanock S, Borresen-Dale AL, Perou CM: Mutation of GATA3 in human breast tumors. Oncogene. 2004, 23: 7669-7678. 10.1038/sj.onc.1207966.CrossRefPubMed
24.
Arnold JM, Choong DY, Thompson ER, Waddell N, Lindeman GJ, Visvader JE, Campbell IG, Chenevix-Trench G: Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat. 2009, 119: 491-496. 10.1007/s10549-008-0269-x.CrossRefPubMed
25.
Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30: 207-210. 10.1093/nar/30.1.207.CrossRefPubMedPubMedCentral
26.
Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL: Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008, 108: 191-201. 10.1007/s10549-007-9596-6.CrossRefPubMed
27.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679. 10.1016/S0140-6736(05)17947-1.CrossRefPubMed
28.
Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66: 10292-10301. 10.1158/0008-5472.CAN-05-4414.CrossRefPubMed
29.
Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L: Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010, 12: R5-10.1186/bcr2468.CrossRefPubMedPubMedCentral
30.
Zhang DH, Yang L, Ray A: Differential responsiveness of the IL-5 and IL-4 genes to transcription factor GATA-3. J Immunol. 1998, 161: 3817-3821.PubMed
31.
Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA: Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001, 15: 50-65. 10.1101/gad.828901.CrossRefPubMedPubMedCentral
32.
Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17: 1253-1270. 10.1101/gad.1061803.CrossRefPubMedPubMedCentral
33.
Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M: Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006, 38: 1289-1297. 10.1038/ng1901.CrossRefPubMed
34.
Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, et al: The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010, 28: 827-838. 10.1038/nbt.1665.CrossRefPubMed
35.
Chou J, Provot S, Werb Z: GATA3 in development and cancer differentiation: cells GATA have it!. J Cell Physiol. 2009, 222: 42-49. 10.1002/jcp.21943.CrossRef
36.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25: 25-29. 10.1038/75556.CrossRefPubMedPubMedCentral
37.
Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou JC: Inhibition of Bax channel-forming activity by Bcl-2. Science. 1997, 277: 370-372. 10.1126/science.277.5324.370.CrossRefPubMed
38.
Popov VM, Wu K, Zhou J, Powell MJ, Mardon G, Wang C, Pestell RG: The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab. 2009, 21: 41-49. 10.1016/j.tem.2009.08.002.CrossRefPubMedPubMedCentral
39.
Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, Zhang Q, Willmarth NE, Chepelev I, Crosariol M, Wei Z, Hu J, Zhao K, Pestell RG: Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem. 2010, 286: 2132-2142. 10.1074/jbc.M110.148395.CrossRefPubMedPubMedCentral
40.
Lee JW, Kim HS, Kim S, Hwang J, Kim YH, Lim GY, Sohn WJ, Yoon SR, Kim JY, Park TS, Park KM, Ryoo ZY, Lee S: DACH1 regulates cell cycle progression of myeloid cells through the control of cyclin D, Cdk 4/6 and p21(Cip1). Biochem Biophys Res Commun. 2012, 420: 91-95. 10.1016/j.bbrc.2012.02.120.CrossRefPubMed
41.
Tsutsui K, Manabe R, Yamada T, Nakano I, Oguri Y, Keene DR, Sengle G, Sakai LY, Sekiguchi K: ADAMTSL-6 is a novel extracellular matrix protein that binds to fibrillin-1 and promotes fibrillin-1 fibril formation. J Biol Chem. 2009, 285: 4870-4882. 10.1074/jbc.M109.076919.CrossRefPubMedPubMedCentral
42.
Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Pestell RG: DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem. 2003, 278: 51673-51684. 10.1074/jbc.M310021200.CrossRefPubMed
43.
Popov VM, Zhou J, Shirley LA, Quong J, Yeow WS, Wright JA, Wu K, Rui H, Vadlamudi RK, Jiang J, Kumar R, Wang C, Pestell RG: The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res. 2009, 69: 5752-5760. 10.1158/0008-5472.CAN-08-3992.CrossRefPubMedPubMedCentral
44.
Kindla J, Rau TT, Jung R, Fasching PA, Strick R, Stoehr R, Hartmann A, Fromm MF, Konig J: Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biol Ther. 2011, 11: 584-591. 10.4161/cbt.11.6.14533.CrossRefPubMed
45.
Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME: GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat. 2005, 92: 141-149. 10.1007/s10549-005-1483-4.CrossRefPubMed
46.
Hutchins JR, Toyoda Y, Hegemann B, Poser I, Heriche JK, Sykora MM, Augsburg M, Hudecz O, Buschhorn BA, Bulkescher J, Conrad C, Comartin D, Schleiffer A, Sarov M, Pozniakovsky A, Slabicki MM, Schloissnig S, Steinmacher I, Leuschner M, Ssykor A, Lawo S, Pelletier L, Stark H, Nasmyth K, Ellenberg J, Durbin R, Buchholz F, Mechtler K, Hyman AA, Peters JM: Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science. 2010, 328: 593-599. 10.1126/science.1181348.CrossRefPubMedPubMedCentral
47.
Shi X, Liu M, Li D, Wang J, Aneja R, Zhou J: Cep70 contributes to angiogenesis by modulating microtubule rearrangement and stimulating cell polarization and migration. Cell Cycle. 2012, 11: 1554-1563. 10.4161/cc.19954.CrossRefPubMed
48.
Shi X, Sun X, Liu M, Li D, Aneja R, Zhou J: CEP70 protein interacts with gamma-tubulin to localize at the centrosome and is critical for mitotic spindle assembly. J Biol Chem. 2011, 286: 33401-33408. 10.1074/jbc.M111.252262.CrossRefPubMedPubMedCentral
49.
Lock FE, Ryan KR, Poulter NS, Parsons M, Hotchin NA: Differential regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One. 2012, 7: e31423-10.1371/journal.pone.0031423.CrossRefPubMedPubMedCentral
50.
Hosono Y, Yamaguchi T, Mizutani E, Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S, Yokoi K, Suzuki M, Takahashi T: MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J. 2011, 31: 481-493. 10.1038/emboj.2011.416.CrossRefPubMedPubMedCentral
51.
Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J: Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001, 3: 346-352. 10.1038/35070019.CrossRefPubMed
52.
Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, Saint-Geniez M, Campaigniac JP, Liao JK, D'Amore PA: RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010, 24: 3186-3195. 10.1096/fj.09-145102.CrossRefPubMedPubMedCentral
53.
Di Bacco A, Gill G: SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle. 2006, 5: 2310-2313. 10.4161/cc.5.20.3367.CrossRefPubMed
54.
Di Bacco A, Ouyang J, Lee HY, Catic A, Ploegh H, Gill G: The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol. 2006, 26: 4489-4498. 10.1128/MCB.02301-05.CrossRefPubMedPubMedCentral
55.
Hoepfner S, Severin F, Cabezas A, Habermann B, Runge A, Gillooly D, Stenmark H, Zerial M: Modulation of receptor recycling and degradation by the endosomal kinesin KIF16B. Cell. 2005, 121: 437-450. 10.1016/j.cell.2005.02.017.CrossRefPubMed
56.
Ueno H, Huang X, Tanaka Y, Hirokawa N: KIF16B/Rab14 molecular motor complex is critical for early embryonic development by transporting FGF receptor. Dev Cell. 2011, 20: 60-71. 10.1016/j.devcel.2010.11.008.CrossRefPubMed
57.
Huang MY, Wang HM, Chang HJ, Hsiao CP, Wang JY, Lin SR: Overexpression of S100B, TM4SF4, and OLFM4 genes is correlated with liver metastasis in Taiwanese colorectal cancer patients. DNA Cell Biol. 2012, 31: 43-49. 10.1089/dna.2011.1264.CrossRefPubMedPubMedCentral
58.
Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, Singer S, Sander C: Functional copy-number alterations in cancer. PLoS One. 2008, 3: e3179-10.1371/journal.pone.0003179.CrossRefPubMedPubMedCentral
59.
Jin H, Pi J, Huang X, Huang F, Shao W, Li S, Chen Y, Cai J: BMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation. Appl Microbiol Biotechnol. 2012, 93: 1715-1723. 10.1007/s00253-011-3865-3.CrossRefPubMed
60.
Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, Harris AL: Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol. 2005, 131: 741-750. 10.1007/s00432-005-0024-1.CrossRefPubMed
61.
Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, Geyer A, Waldau A, Hortschansky P, Schmidt A, Hoffken K, Wolft S, Harris AL: Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol. 2005, 27: 401-407.PubMed
62.
Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS: Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001, 21: 4265-4275. 10.1128/MCB.21.13.4265-4275.2001.CrossRefPubMedPubMedCentral
63.
Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE: The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006, 66: 6412-6420. 10.1158/0008-5472.CAN-05-2368.CrossRefPubMed
64.
Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM: A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell. 2012, 10: 183-197. 10.1016/j.stem.2011.12.018.CrossRefPubMedPubMedCentral
65.
Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69: 1302-1313. 10.1158/0008-5472.CAN-08-2741.CrossRefPubMedPubMedCentral
66.
Pei XH, Bai F, Smith MD, Usary J, Fan C, Pai SY, Ho IC, Perou CM, Xiong Y: CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell. 2009, 15: 389-401. 10.1016/j.ccr.2009.03.004.CrossRefPubMedPubMedCentral
67.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2: 401-404. 10.1158/2159-8290.CD-12-0095.CrossRefPubMed
68.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013, 6: l1-10.1126/scisignal.2004088.CrossRef
69.
Ho IC, Tai TS, Pai SY: GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 2009, 9: 125-135. 10.1038/nri2476.CrossRefPubMedPubMedCentral
70.
Vargo-Gogola T, Rosen JM: Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007, 7: 659-672. 10.1038/nrc2193.CrossRefPubMed
71.
Beelen K, Zwart W, Linn SC: Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol. 2012, 9: 529-541. 10.1038/nrclinonc.2012.121.CrossRefPubMed
72.
Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE: Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007, 9: 201-209. 10.1038/ncb1530.CrossRefPubMed
73.
Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP: The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol. 2009, 40: 489-495. 10.1016/j.humpath.2008.09.010.CrossRefPubMed
74.
Yoon NK, Maresh EL, Shen D, Elshimali Y, Apple S, Horvath S, Mah V, Bose S, Chia D, Chang HR, Goodglick L: Higher levels of GATA3 predict better survival in women with breast cancer. Hum. Pathol. 2010, 41: 1794-1801. 10.1016/j.humpath.2010.06.010.CrossRefPubMedPubMedCentral
75.
Woon Kim Y, Kim S, Geun Kim C, Kim A: The distinctive roles of erythroid specific activator GATA-1 and NF-E2 in transcription of the human fetal gamma-globin genes. Nucleic Acids Res. 2011, 39: 6944-6955. 10.1093/nar/gkr253.CrossRefPubMedPubMedCentral
76.
Shimotsuma M, Okamura E, Matsuzaki H, Fukamizu A, Tanimoto K: DNase I hypersensitivity and epsilon-globin transcriptional enhancement are separable in locus control region (LCR) HS1 mutant human beta-globin YAC transgenic mice. J Biol Chem. 2010, 285: 14495-14503. 10.1074/jbc.M110.116525.CrossRefPubMedPubMedCentral
77.
Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009, 14: 3-9. 10.1007/s10911-009-9109-9.CrossRefPubMed
78.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral
79.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490: 61-70. 10.1038/nature11412.CrossRef
80.
Takemoto N, Arai K, Miyatake S: Cutting edge: the differential involvement of the N-finger of GATA-3 in chromatin remodeling and transactivation during Th2 development. J Immunol. 2002, 169: 4103-4107. 10.4049/jimmunol.169.8.4103.CrossRefPubMed
81.
Gaynor KU, Grigorieva IV, Allen MD, Esapa CT, Head RA, Gopinath P, Christie PT, Nesbit MA, Jones JL, Thakker RV: GATA3 mutations found in breast cancers may be associated with aberrant nuclear localization, reduced transactivation and cell invasiveness. Horm Cancer. 2013, 4: 123-139. 10.1007/s12672-013-0138-x.CrossRefPubMed
Metadata
Title
Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer
Authors
Helit Cohen
Rotem Ben-Hamo
Moriah Gidoni
Ilana Yitzhaki
Renana Kozol
Alona Zilberberg
Sol Efroni
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-014-0464-0

Other articles of this Issue 6/2014

Breast Cancer Research 6/2014 Go to the issue

Review

Estrogen receptor mutations and their role in breast cancer progression

Research article

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy

Letter

HER2 expression and efficacy of T-DM1

Research article

Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis

Research article

A migrant study of pubertal timing and tempo in British-Bangladeshi girls at varying risk for breast cancer

Review

Role of bone-anabolic agents in the treatment of breast cancer bone metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits